Literature DB >> 25868851

Associations between pre-S deletion mutation of hepatitis B virus and risk of hepatocellular carcinoma in the Asian population: a meta-analysis.

Chao Wang1, Zhaowei Teng2, Yun Zhu2, Allan Z Zhao1, Chunhua Sun3.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the most common liver cancer, leading to many cancer-related deaths worldwide. Several studies have shown an association between pre-S deletion mutation of hepatitis B virus (HBV) and HCC risk, but the results remain conflicting. We aimed to verify HBV pre-S deletion mutations in relation to the risk of HCC.
MATERIAL AND METHODS: We searched the commonly used electronic databases for relevant studies of this association among the Asian population until September 30th, 2014. Odds ratios (ORs) with 95% confidence intervals (CIs) were employed to calculate the association.
RESULTS: A total of 17 case-control studies were screened out, including 2837 HBV-infected patients, of whom 1246 had HCC. The results showed that the frequency of pre-S deletion of HBV in patients with HCC was higher than that in patients without HCC (35.7% vs. 11.5%), indicating the prevalence of this mutation in patients with HCC. Statistically significant correlations were observed for pre-S deletion mutation and risk of HCC in a random-effects model (OR=3.90, 95% CI=2.80-5.44, P<0.00001). This association was also found in Chinese populations (OR=4.84, 95% CI=2.86-8.20, P<0.00001).
CONCLUSIONS: Our data indicate that HBV pre-S deletion mutations might be associated with HCC risk. Their oncogenic role may be important in studying the potential mechanism of HBV hepatocarcinogenesis.

Entities:  

Mesh:

Year:  2015        PMID: 25868851      PMCID: PMC4410724          DOI: 10.12659/MSM.894058

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


Background

Hepatocellular carcinoma (HCC) is the most common solid tumor worldwide, and is the leading factor responsible for cancer mortality [1]. Most HCCs occur in China, Southeast Asia, and in parts of Africa [2]. The main risk factors contributing to the occurrence of HCC are virus-induced chronic infection caused by hepatitis C virus (HCV) or hepatitis B virus (HBV), alcohol abuse, liver cirrhosis, exposure to aflatoxin B1, and diabetes [3]. Among these, HBV is a major etiologic agent and is causes 80% of HCC cases. Furthermore, HBV-related liver disease is the major reason for liver transplantation [4,5]. Research has estimated that both genetic and viral factors are crucial for the development of HCC; however, the exact mechanism leading to HBV tumorigenesis has not yet been fully elucidated [6-8]. HBV is a small, enveloped, double-stranded DNA virus. It contains 4 main regions: the pre-S/S region, the enhancer II region, basal core promoter region, and the precore region [9]. Several HBV mutant strains in these regions were reported to contribute to the progression of liver disease [10]. One of the most commonly reported HBV mutations is the pre-S region deletion mutation. The pre-S proteins are produced from the surface gene (S gene) region, including 3 different translation sites: pre-S1, pre-S2, and S [11]. The pre-S protein is reported to be involved in hepatocyte attachment of the virus [12] and contains B cell and T cell epitopes [13]. The B cell and T cell epitopes are binding sites for neutralizing anti-pre-S2 antibody. An S promoter has been identified in pre-S that is associated with the production of middle and small HBs [11]. The pre-S1 and pre-S2 regions are crucial for the interplay within the host immune responses [14]. Numerous reports of mechanisms suggested that deletion mutations in pre-S in the integrated HBV DNA may impair the secretion of HBsAg, leading to increased endoplasmic reticulum and oxidative stress in hepatocytes [15]. Recent studies have demonstrated that pre-S mutations affect the severity of liver disease; its mutation generally presents in the form of deletions [16,17]. Studies have determined that mutation of the promoter sites of pre-S1 and pre-S2 significantly increase the risk of HCC development [18,19]; however, a clinical study [20] study has shown that the pre-S internal deletion mutants are unlikely to play crucial roles in hepatocarcinogenesis. These discrepancies may be due to genetic trait differences and different linkage disequilibrium. Therefore, in order to derive a more comprehensive estimation of the associations between pre-S deletion mutation and HCC risk, we conducted a meta-analysis to assess the relationship only among Asians.

Material and Methods

Literature search

An electronic literature search was conducted using PubMed, Embase, and China National Knowledge Infrastructure (CNKI) databases until September 30th, 2013. The Medical Subject Heading (MeSH) terms “hepatitis B virus,” “HBV,” “pre-S deletion,” “mutation,” “hepatocellular carcinoma”, and the individual corresponding free terms were employed as the searching words. In addition, the citations in the retrieved articles were reviewed to search for relevant studies.

Criteria for article screening

The studies included met the following criteria: 1) assessed the association between pre-S mutations of HBV and HCC risk; 2) case-control or cohort study; 3) the diagnosis of liver disease followed the guidelines of the American Association for the Study of Liver Diseases [14,21], and matched HBV-infected non-HCC cases as controls; 4) odds ratio with the 95% confidence interval (CI) was reported or could be determined from the available data; and 5) Asian population.

Data extraction

Two investigators independently assessed the extracted data from the included studies and reached a consensus on final results. Any disagreement was resolved by discussing with a third expert. The following information was extracted from all obtained publications: first author’s name, publication year, country or area, the number of included patients, and the number of deletion mutations. We extracted data on the participants whose mutation status had been determined. Our evaluation included deletions in pre-S1 and/or pre-S2 that were predicted or known to decrease pre-S or S expression.

Statistical analysis

Statistical analyses were carried out using Review Manager 5.2 (The Cochrane Collaboration). The crude odds ratios (ORs) and their corresponding 95% CI were used as a measure of the associations between HBV pre-S deletion mutation and risk of HCC. The overall effect was evaluated through the Z test. P value less than 0.05 was deemed to be statistically significant. The heterogeneity between all the included articles was evaluated by the Q test and the I2 statistics. P value less than 0.1 and I2 less than 50% was considered to be statistically significant. A fixed- or random-effects model was used to estimate the heterogeneity. A fixed-effects model was used when the effects were assumed to be homogenous, and a random-effects model was used when they were heterogenous. A funnel plot test was performed to examine publication bias.

Results

Study selection

Our search strategy yielded 316 papers. We reviewed the titles, abstracts, and full texts of all retrieved articles using the defined criteria. Finally, 17 studies evaluating the relationship between pre-S deletion mutation of HBV and risk of HCC were selected in our meta-analysis. Figure 1 shows the flow diagram. Characteristics of the included studies are shown in Table 1. Of the 17 included studies, 8 were from mainland China [17,22-29], 3 were from Taiwan [16,30,31], 1 was from Thailand [32], 4 were from South Korea [33-36], and 1 was from mixed Asian countries [37]. These studies included 2837 HBV-infected participants, of whom 1246 had HCC.
Figure 1

Studies identified with criteria for inclusion and exclusion.

Table 1

Characteristics of studies included in this meta-analysis.

First authorYearCountryMean ageControl typeSample sizeNo. of deletion mutations
CasesControlsCases/controlsCasesControls
Choi MS2007Korean51.9±7.839.4±12.2AC+CH+LC72/2281116
Gao ZY2007China55.56±12.2820.04±0.89AC+CHB26/53103
Mun H2008Korean47.9±17.347.9±17.3AC+CH+LC40/802116
Fang ZL2008China30–5530–55Non-HCC33/33156
Chen C2008Taiwan50.7±11.348.9±10.6Non-HCC80/1602827
Cao ZG2008China42.1±8.839.9±12.4CH47/50249
Jang JS2009South KoreaNon-HCC48/711713
Abe K2009Four countries11±36±5CH30/10230
Wu XD2010China46.7±10.745.8±13.3AC44/43216
Yin JH2010China49.9±11.030.0±16.9AC231/6039443
Huang H2010Taiwan12.7±6.612.3±0.8CH19/1991
Yeung P2011Taiwan56.9±11.556.8±11.5Non-HCC96/962814
Qiang FL2011China42–6721–39AC26/2560
Lee MH2011Korean44.3±7.844.3±8.0Non-HCC135/135256
Thongbai C2013Thailand58.1±12.041.3±8.8Non-HCC65/89119
Zhao ZM2014ChinaNon-HCC157/1607445
Qu LS2014China44.2±9.545.0±8.3Non-HCC97/962811

AC – asymptomatic carrier; CH – chronic hepatitis; LC – liver cirrhosis; HCC – hepatocellular carcinoma; ‘–’ – not applicable.

Pre-S deletions and the risk of HCC

We mainly focused on the pre-S deletion mutation in this meta-analysis. As shown in Figure 2, we observed a statistically significant association between pre-S deletion mutation and HCC risk. The data show that patients with HCC had more HBV with pre-S deletions than patients without HCC (35.7% vs. 11.5%). The overall risk estimates OR for HCC of pre-S deletion was 3.90 (95% CI=2.80–5.44, P<0.00001) in a random-effects model. When only considering the Chinese population, our results found that the pre-S deletions were significantly associated with HCC risk (OR=4.84, 95% CI=2.86–8.20, P<0.00001).
Figure 2

Forest plot for the correlation between pre-S deletion and HCC risk. Pooled odds ratio for the association of pre-S deletion mutation and HCC risk using random-effects model.

Sensitivity analysis

For this meta-analysis, the ORs were not significantly changed by deleting any single study, indicating that no individual study affected the statistical significance of the overall results.

Publication bias

Publication bias was found in pre-S deletion mutation studies and funnel plot analysis showed that the study by Yin et al. was the outlier. After removing this study, the between-study heterogeneity decreased from 59% to 20%. Figure 3A, 3B display the funnel plots for the associations between pre-S deletion and HCC risk before and after omitting this report.
Figure 3

Funnel plots analysis to detect publication bias of pre-S deletion mutation before (A) and after (B) three studies omitting. Each point represents an independent study for the indicated association.

Discussion

The pre-S region of HBV is located at 5′ of the S gene, and pre-S is composed of pre-S1 and pre-S2. Natural pre-S mutations of HBV have been frequently observed in chronic HBV infections [38]. Pre-S region deletion mutation is known to be a risk factor for hepatocarcinogenesis and often occurs in patients treated with interferon. This suggests attempts by the virus to evade host immune response [39]. Pre-S1 region deletion and pre-S2 region deletion are 2 common variants in the pre-S region. The deletion in the pre-S region results in the dysfunctional immune response and hepatocyte pathogenesis [40], finally leading to the occurrence of HCC. Thus, these mutations might be used as biomarkers in predicting the development of HCC. We identified an association of pre-S deletion mutation with HCC risk in this meta-analysis. The results showed that pre-S mutation statistically correlates with the significantly increased risk of HCC. The pooled crude ORs from the included studies suggest that pre-S mutation is associated with 4.64-fold increased risk of HCC compared with wild-type HBV (without mutations) (95% CI= 2.92–8.12, P<0.00001) in a random-effects model. To determine if specific pre-S mutations correlate with increased risk of HCC occurrence, we compared and analyzed the deleted portions of pre-S region in HBV-infected patients with or without HCC. We found that the 5′-terminal half of pre-S2 (nucleotides 3206-60) was the most commonly deleted portion of the pre-S region but that the frequency of this deletion in patients with and without HCC showed no significant statistical difference. Although many studies have suggested the close relationship of pre-S deletions with the prevalence of HCC, they were mainly based on cross-sectional studies without thoroughly considering various possible confounding factors. Male sex, older age, and infection with HBV are the main risk factors for HCC occurrence [41,42]. Older age and HBV genotype C are closely linked to the presence of pre-S deletions [18,43]. The potential effect of the interaction of these factors should be considered in studying the role of pre-S deletions in HCC development in further research. Several potential limitations exist in this meta-analysis. First, the observed association is substantially based on cross-sectional studies without considering other possible confounding factors. Second, publication biases cannot be completely excluded because all of the included studies were mainly relying on observation. Third, our study only focused on pre-S deletion mutation and we needed to also identify single-base substitutions at the pre-S1 and pre-S2 start codon. Fourth, all studies utilized in this meta-analysis were performed in eastern Asia, where HBV is endemic. Fifth, the control cases were not consistent; therefore, our results may not be generalizable to populations infected by other HBV genotypes. Furthermore, articles published in other languages were not incorporated into this analysis due to the anticipated difficulties in acquiring accurate medical translation.

Conclusions

Despite the above limitations, our results show that pre-S mutations are associated with the increased risk of HCC development. However, large-scale, well-designed, case-control studies concentrating on the epigenetic influence and the genetic variations are still needed to prove this association.
  41 in total

1.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

2.  Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen.

Authors:  D R Milich; G B Thornton; A R Neurath; S B Kent; M L Michel; P Tiollais; F V Chisari
Journal:  Science       Date:  1985-06-07       Impact factor: 47.728

3.  Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B.

Authors:  Pok Yeung; Danny Ka-Ho Wong; Ching-Lung Lai; James Fung; Wai-Kay Seto; Man-Fung Yuen
Journal:  J Infect Dis       Date:  2011-01-12       Impact factor: 5.226

Review 4.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

5.  Pre-S2 deletions of hepatitis B virus and hepatocellular carcinoma in children.

Authors:  Hsiang-Po Huang; Hong-Yuan Hsu; Chi-Ling Chen; Yen-Hsuan Ni; Hurng-Yi Wang; Daw-Jen Tsuei; Cheng-Lun Chiang; Yi-Chen Tsai; Huey-Ling Chen; Mei-Hwei Chang
Journal:  Pediatr Res       Date:  2010-01       Impact factor: 3.756

6.  Novel approach to identifying the hepatitis B virus pre-S deletions associated with hepatocellular carcinoma.

Authors:  Zhi-Mei Zhao; Yan Jin; Yu Gan; Yu Zhu; Tao-Yang Chen; Jin-Bing Wang; Yan Sun; Zhi-Gang Cao; Geng-Sun Qian; Hong Tu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

7.  Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease.

Authors:  Fuminaka Sugauchi; Tomoyoshi Ohno; Etsuro Orito; Hiroshi Sakugawa; Takafumi Ichida; Masafumi Komatsu; Tomoyuki Kuramitsu; Ryuzo Ueda; Yuzo Miyakawa; Masashi Mizokami
Journal:  J Med Virol       Date:  2003-08       Impact factor: 2.327

8.  Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma.

Authors:  Naota Taura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Eisuke Ozawa; Takuya Tsutsumi; Shotaro Tsuruta; Yuji Kato; Takashi Goto; Noboru Kinoshita; Masanori Fukushima; Hiroyuki Kato; Kazuyuki Ohata; Kazuo Ohba; Junichi Masuda; Keisuke Hamasaki; Hiroshi Yatsuhashi; Kazuhiko Nakao
Journal:  Med Sci Monit       Date:  2013-09-06

9.  Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients.

Authors:  Masashi Tatsukawa; Akinobu Takaki; Hidenori Shiraha; Kazuko Koike; Yoshiaki Iwasaki; Haruhiko Kobashi; Shin-Ichi Fujioka; Kohsaku Sakaguchi; Kazuhide Yamamoto
Journal:  BMC Cancer       Date:  2011-10-21       Impact factor: 4.430

10.  Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study.

Authors:  Zhong-Liao Fang; Caroline A Sabin; Bai-Qing Dong; Shao-Chao Wei; Qin-Yan Chen; Kong-Xiong Fang; Jin-Ye Yang; Jian Huang; Xue-Yan Wang; Tim J Harrison
Journal:  J Gen Virol       Date:  2008-11       Impact factor: 3.891

View more
  9 in total

1.  Lost Small Envelope Protein Expression from Naturally Occurring PreS1 Deletion Mutants of Hepatitis B Virus Is Often Accompanied by Increased HBx and Core Protein Expression as Well as Genome Replication.

Authors:  Shuwen Fu; Jing Zhang; Quan Yuan; Qianru Wang; Qiang Deng; Jisu Li; Ningshao Xia; Yongxiang Wang; Yumei Wen; Shuping Tong
Journal:  J Virol       Date:  2021-06-24       Impact factor: 5.103

2.  Clustering infection of hepatitis B virus genotype B4 among residents in Vietnam, and its genomic characters both intra- and extra-family.

Authors:  Junko Matsuo; Son Huy Do; Chikako Yamamoto; Shintaro Nagashima; Channarena Chuon; Keiko Katayama; Kazuaki Takahashi; Junko Tanaka
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

3.  Preoperative Phenacetin Metabolism Test in the Prediction of Postoperative Liver Dysfunction of Patients with Hepatocellular Carcinoma.

Authors:  Xiaohua Pan; Xiaodong Li; Liqing Cui; Qianwei Wang
Journal:  Med Sci Monit       Date:  2017-05-29

4.  Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study.

Authors:  Nicola Coppola; Lorenzo Onorato; Valentina Iodice; Mario Starace; Carmine Minichini; Nunzia Farella; Giulia Liorre; Pietro Filippini; Evangelista Sagnelli; Giorgio de Stefano
Journal:  Oncotarget       Date:  2016-09-20

Review 5.  New perspectives of biomarkers for the management of chronic hepatitis B.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  Clin Mol Hepatol       Date:  2016-12-25

6.  Sex disparity in viral load, inflammation and liver damage in transgenic mice carrying full hepatitis B virus genome with the W4P mutation in the preS1 region.

Authors:  Seoung-Ae Lee; So-Young Lee; Yu-Min Choi; Hong Kim; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2018-03-14       Impact factor: 5.742

Review 7.  Endoplasmic Reticulum Stress Signaling and the Pathogenesis of Hepatocarcinoma.

Authors:  Juncheng Wei; Deyu Fang
Journal:  Int J Mol Sci       Date:  2021-02-11       Impact factor: 5.923

8.  Deep sequencing of HBV pre-S region reveals high heterogeneity of HBV genotypes and associations of word pattern frequencies with HCC.

Authors:  Xin Bai; Jian-An Jia; Meng Fang; Shipeng Chen; Xiaotao Liang; Shanfeng Zhu; Shuqin Zhang; Jianfeng Feng; Fengzhu Sun; Chunfang Gao
Journal:  PLoS Genet       Date:  2018-02-23       Impact factor: 5.917

9.  Genotypes and Hot Spot Mutations of Hepatitis B Virus in Northwest Chinese Population and Its Correlation with Diseases Progression.

Authors:  Wei Wang; Yi Shu; Han Bao; Wenliang Zhao; Weihua Wang; Qin Wang; Xiaoying Lei; Daxiang Cui; Zhen Yan
Journal:  Biomed Res Int       Date:  2019-12-10       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.